LEARN ABOUT THIS STUDY – WITH STUDY CENTERS IN USA AND OUTSIDE OF USA HERE: https://cypress-study.com/
Theravance Biopharma is researching the investigational drug (ampreloxetine) because they believe it may reduce nOH symptoms that interfere with daily activity in MSA patients based on prior clinical trial results. They are running the Phase 3 CYPRESS trial to confirm whether the investigational drug is effective and safe in treating nOH symptoms in MSA patients and to learn about any unwanted side effects.
Neurogenic Orthostatic Hypotension involves issues with regulating blood pressure. Many people diagnosed with MSA may exhibit nOH symptoms.
